KR20240042443A - 신경계 질환을 치료하는 방법 - Google Patents

신경계 질환을 치료하는 방법 Download PDF

Info

Publication number
KR20240042443A
KR20240042443A KR1020247004608A KR20247004608A KR20240042443A KR 20240042443 A KR20240042443 A KR 20240042443A KR 1020247004608 A KR1020247004608 A KR 1020247004608A KR 20247004608 A KR20247004608 A KR 20247004608A KR 20240042443 A KR20240042443 A KR 20240042443A
Authority
KR
South Korea
Prior art keywords
antibody
binding fragment
antigen
antigen binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247004608A
Other languages
English (en)
Korean (ko)
Inventor
슈이-온 리앙
치호 총
칭이 추앙
Original Assignee
시노맙 바이오사이언스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시노맙 바이오사이언스 리미티드 filed Critical 시노맙 바이오사이언스 리미티드
Publication of KR20240042443A publication Critical patent/KR20240042443A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020247004608A 2021-07-13 2022-07-12 신경계 질환을 치료하는 방법 Pending KR20240042443A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221261P 2021-07-13 2021-07-13
US63/221,261 2021-07-13
PCT/CN2022/105077 WO2023284710A1 (en) 2021-07-13 2022-07-12 Methods of treating neurological diseases

Publications (1)

Publication Number Publication Date
KR20240042443A true KR20240042443A (ko) 2024-04-02

Family

ID=84919904

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247004608A Pending KR20240042443A (ko) 2021-07-13 2022-07-12 신경계 질환을 치료하는 방법

Country Status (10)

Country Link
US (1) US20240309089A1 (https=)
EP (1) EP4370153A4 (https=)
JP (1) JP2024527401A (https=)
KR (1) KR20240042443A (https=)
CN (1) CN117999096A (https=)
AU (1) AU2022310081A1 (https=)
CA (1) CA3225077A1 (https=)
MX (1) MX2024000591A (https=)
WO (1) WO2023284710A1 (https=)
ZA (1) ZA202400405B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710471A1 (en) * 2017-11-16 2020-09-23 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
WO2024197258A1 (en) * 2023-03-23 2024-09-26 Klaritos, Inc Methods of treating alzheimer's disease
WO2025190311A1 (en) * 2024-03-12 2025-09-18 Sinomab Bioscience Limited Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
AU2014305658A1 (en) * 2013-08-05 2016-02-11 St. Vincent's Institute Of Medical Research An antibody therapy for amyloid beta disease
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer

Also Published As

Publication number Publication date
JP2024527401A (ja) 2024-07-24
WO2023284710A1 (en) 2023-01-19
EP4370153A1 (en) 2024-05-22
ZA202400405B (en) 2025-03-26
EP4370153A4 (en) 2025-05-07
MX2024000591A (es) 2024-03-19
CA3225077A1 (en) 2023-01-19
CN117999096A (zh) 2024-05-07
AU2022310081A1 (en) 2024-02-01
US20240309089A1 (en) 2024-09-19

Similar Documents

Publication Publication Date Title
KR101713365B1 (ko) 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
JP5890174B2 (ja) 終末糖化産物受容体（ｒａｇｅ）に対する抗体及びその使用
AU2022203601A1 (en) Therapeutic antibodies and their uses
KR100767146B1 (ko) Ａβ 펩티드를 격리시키는 인간화 항체
TWI449535B (zh) 針對類澱粉- β肽之抗體於治療年齡相關黃班退化之用途
KR20190130133A (ko) 항-phf-타우 항체 및 이의 용도
KR20100021650A (ko) 아밀로이드 베타에 대해 인간화된 항체
JP7539834B2 (ja) ガレクチン－３に対する抗体及びその使用方法
KR20170085595A (ko) 혈뇌 장벽 수용체 항체 및 사용 방법
TWI866304B (zh) 抗EphA4抗體
WO2023284710A1 (en) Methods of treating neurological diseases
TW202142569A (zh) 抗cd98抗體及其用途
CN115697393A (zh) 抗PHF-tau抗体及其用途
US20240150451A1 (en) Anti-tau antibodies and uses thereof
WO2023202553A1 (en) Methods of treating neurological diseases
HK40109637A (zh) 治疗神经学疾病的方法
HK40121519A (zh) 治疗神经系统疾病的方法
TW202509070A (zh) Bdca2-標靶抗體及其用途
IL323380A (en) Antibodies directed against IL-7 and their uses
HK1240242A1 (en) Blood brain barrier receptor antibodies and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201